A Phase I, Open-Label, Dosage Escalation, Study of Multiple Doses of CAVATAK (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gebasaxturev (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Biomarker
Sponsors Viralytics

Most Recent Events

18 Jan 2012 Status changed from recruiting to discontinued, according to a Viralytics media release.
11 Nov 2011 Recruitment is not progressing as anticipated and Viralytics is re-evaluating the strategic value of this trial.
02 Feb 2011 Planned end date changed from Jun 2010 to Jun 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight